Protein phosphatase 2A (PP2A) is a heterotrimeric serine/threonine phosphatase that has multiple inhibitory roles in cell proliferation and metastasis and promotes tumor suppressor activity. Protein methylesterase 1 (PME-1) inhibits PP2A through the removal of a methyl group from its catalytic subunit. Here, we discuss emerging reports that (1) PME-1 is over-expressed in cancer, (2) PME-1 inhibits PP2A activity and promotes cancer progression, and (3) can be chemically inhibited in vivo. We further show that PME-1 may have an important role in Wnt signaling in endometrial cancer that has yet to be fully explored and demonstrate that post-translational modifications of PP2A may play a role in PME-1 binding. Discussed within, the current literature supports continued evaluation of PME-1 as a potential therapeutic target and biomarker for cancer.
Introduction
Protein phosphatase 2A (PP2A) is a heterotrimeric serine/threonine phosphatase that is implicated as a tumor suppressor (reviewed in [1] [2] [3] ). PP2A is a positive regulator of canonical tumor suppressors, such as p53 and p21 [4] [5] [6] , but also has multiple roles in the inhibition of cell proliferation promoting pathways, such as Akt and ERK [7] [8] [9] [10] [11] . PP2A inactivation is thought to be a critical step in cell transformation [12] [13] [14] [15] and chemically reactivating PP2A is a viable therapeutic strategy as PP2A is rarely mutated in tumors. Activation of PP2A could lead to the broad inhibition of several cell signaling pathways while supporting the activity of tumor suppressors.
Some recent work has focused on the identification, mechanistic elucidation, and inhibition of PP2A inhibitors. Cancerous inhibitor of PP2A (CIP2A) and SET proteins interact with various PP2A subunits to inhibit PP2A activity [16] [17] . Though protein-protein interactions (PPI) are difficult to inhibit with small molecules, there has been some success in preventing the association of SET and PP2A using the small molecule, FTY720 [13, [18] [19] and the cell-permeable peptide, OP449 [20] . To date, no CIP2A-
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PP2A PPI inhibitors have been reported, although targeting the Ets1 family of transcription factors, which are required for CIP2A expression, has been suggested as a potential therapeutic strategy [21] [22] . PP2A is comprised of the A scaffolding subunit, the C catalytic subunit, and a B regulatory subunit that provides the complex with substrate specificity [2] . The catalytic subunit is coded for by two genes, PPP2CA and PPP2CBthat produce highly identical proteins, Ppp2ca and Ppp2cb, respectively. The C-terminal tail of the catalytic subunit is highly modified and can be phosphorylated on threonine 304 (T304) and tyrosine 307 (Y307) or methylated on leucine 309 (L309). Both phosphorylation events are thought to be inhibitory (reviewed in [23] ), while leucine carboxymethyltransferase (LCMT1)-mediated association and methylation of L309 is thought to activate PP2A and promote B subunit association [24] . Protein methylesterase 1 (PME-1) is a serine hydrolase that demethylates L309 of the catalytic subunit of PP2A. PME-1 has recently been suggested to promote cancerous phenotypes through inhibition of PP2A leading to stabilization of Akt and ERK signaling [25] [26] [27] . Here, we will focus on the elucidation of the role of PME-1 in cancer progression and will discuss its validity as a diagnostic and therapeutic target. . PME-1 modulation may affect Wnt signaling activation. RL95-2 endometrial carcinoma cells stably expressing empty vector (Empty), over-expressing PME-1 (+PME-1), scrambled shRNA (shSCR), or shRNA against PME-1 (shPME-1) were analyzed by qPCR to determine the mRNA expression levels of A, B, PME-1, C, D, the Wnt signaling inhibitor, SFRP1, and E, F, the Wnt signaling activators, WNT3 and WNT3A. Data was analyzed with the student's t test to determine statistical significance, where *p < 0.05, **p < 0.01, ***p < 0.001.
Materials and Methods
Cell growth and RNA interference. RL95-2 and ECC-1 endometrial adenocarcinoma cells were purchased from ATCC and were maintained as suggested and as previously described [27] . Note that recent work has demonstrated that the ECC-1 cell line is genetically similar and redundant to the Ishikawa endometrial adenocarcinoma cell lines [28] . We authenticated all cell lines in November of 2013 (Genetica DNA Laboratories).
Lentivirus was produced in HEK293T cell lines with pLKO shRNA vectors (Thermo Scientific) and pLKO PME-1 over-expression vector (Genecopeia) with pPACKH1 packaging plasmid (System Biosciences, Inc.). Lentivirus was collected and concentrated with Peg-IT concentrating solution (System Biosciences, Inc.). 5.0x10 6 ifu/ml lentiviral particles were added to cell cultures with growth medium and 8 µg/ml PolyBrene (Sigma Aldrich). Medium was changed to full growth medium after 24 hrs and to selection medium containingantibiotic after 48 hrs (5 µg/ml puromycin, Invivogen), and maintained for 10 days. Knock-down and over-expression were validated by RT-PCR and western analysis Taqman RT-PCR Analysis. RNA was extracted with the Qiagen RNAEasy kit. RNA was treated with DNase I (Life Technologies) prior to cDNA synthesis. cDNA was synthesized using 500 ng of RNA and SuperScript VILO cDNA mix (Life Technologies). Taqman Array Human WNT Pathway (Life Technologies) was completed once per cell line with 500 ng cDNA. Validation was completed with Taqman probes of interest. Taqman probes and PCRmix were purchased from Life Technologies. All samples were run in triplicates. Results are representative of three independent experiments in which genes of interest were normalized to the house-keeping gene GAPDH. Gene expression levels were determined by the delta Ct method using GAPDH levels as a reference.
Co-immunoprecipitation and western analysis. ECC-1 cells were co-transfected with FLAG-tagged empty vector, FLAG-Ppp2cb wild-type or mutants, and V5-PME-1 S156A, an inactive mutant of PME-1. Forty-eight hours post-transfection, total cell lysates (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail (Roche)) were subjected to immunoprecipitation using anti-FLAG resin (Sigma) followed by immunoblotting with anti-Flag antibody (Sigma) and anti-V5 antibody (Invitrogen).
Results and Discussion

PME-1 Structure and Function
LCMT1 is vital for PP2A activation [24] and PP2A methylation has been suggested to promote the association of certain B regulatory subunits, such as B/55α [29] [30] [31] [32] . PME-1 was first identified to bind and demethylate PP2A by Lee and colleagues [33] and was shown to associate with inactive forms of PP2A [34] . Though PME-1 has been described as specific for PP2A, we recently demonstrated that PME-1 also associates with the catalytic subunit of protein phosphatase 4 (PP4), suggesting that PP4 may be another substrate for PME-1 [27] . Regulation of PP4 activity by methylation/demethylation has not yet been elucidated.
Over-expression of PME-1 in several cell lines has been correlated to increased Akt and/or ERK signaling, increased cancerous phenotypes, and decreased PP2A activity [25] [26] [27] . Since PP2A regulates multiple signaling pathways, we completed microarray experiments to determine what pathways might be affected due to modulation of PME-1 levels in endometrial cancer (EC). One pathway that we identified and were able to confirm by qPCR analysis was the Wnt signaling pathway. Wnts are glycoproteins that bind to the Frizzled (FZD) receptors and can activate multiple pathways, such as the canonical β-catenin pathway, which up-regulates cell proliferation/epithelial-to-mesenchymal transition (EMT) promoting genes. Wnt-FZD interactions can also lead to activation of the planar cell polarity (PCP) and Ca2+-dependent pathways that promote metastasis. There are other signaling molecules, such as secreted frizzled like protein 1 (SFRP1) that compete for Wnt binding to FZD receptors and decrease Wnt signaling activity (reviewed in [35] ).
We demonstrate that PME-1 over-expression leads to a drastic increase in the Wnt3 and Wnt3a mRNA levels and a concomitant significant decrease in the Wnt signaling inhibitor, SFRP1, mRNA levels ( Figure 1 ). These data suggest that PME-1 may promote more aggressive cell growth, EMT, and metastasis through activation of Wnt signaling. Indeed, we have shown that PME-1 promotes invasive growth in in vitro assays in EC cell lines [27] . Importantly, we demonstrated that over-expression of PME-1 led to increased tumor growth in an in vivo xenograft model [27] . Taken together, these results suggest that PME-1 is a valid cancer target.
Though RNAi-based studies have suggested that PME-1 depletion is beneficial, the question remains if PME-1 inhibition is a viable therapeutic target [25] [26] [27] . PME-1 purified from E. coli has been crystallized both alone and bound to the AC core dimer of PP2A [36] . PME-1 associates with the catalytic subunit of PP2A in two steps. First, PME-1 contacts the active site of PP2A leading to the opening of the active site of PME-1 and displaces metal ions in the catalytic site of PP2A. Second, the C-terminal tail of the catalytic subunit of PP2A enters the active site of PME-1 and is demethylated [36] . This mechanism of PME-1-mediated inactivation of PP2A suggests difficulty in targeting PME-1 due to the high local concentration of PME-1 substrate (i.e. the C-terminal tail of PP2A) when PME-1 is active (Figure 2 ).There is evidence that posttranslational modifications of the Ppp2ca/b C-terminal tail may be important for the targeting of PME-1 to its substrate. Yu and colleagues demonstrated that phosphorylation sites on the catalytic tail were important for methylation competence and B subunit binding [37] . Specifically, they showed that point mutations at T304 did not affect methylation competence, although the phosphorylation status did seem important for B55/α binding. Interestingly, they demonstrated that the Y307F mutation, which would mimic an unphosphorylated residue, did not affect methylation competence or B subunit binding. Their findings are in line with our data. We show that PME-1 is unable to bind the PP2A catalytic subunit, Ppp2cb, when the C-terminal tail is deleted (∆10) or when we mutate Y307 to a phenylalanine residue, suggesting that PME-1 may require phosphorylated Y307 for recognition of the catalytic subunit (Figure 3 ). Note that phosphorylation on T304 does not appear to be required. Taken together, these data suggest that the C-terminal tail of the catalytic subunit of PP2A may act as a signaling molecule for recruitment of LCMT1, PME-1, and even B regulatory subunits.
Inhibition of PME-1
Our studies have demonstrated that depletion of PME-1 via RNAi leads to decreased cell proliferation, invasive growth, and increased PP2A activity in EC cell lines [27] . Depletion of PME-1 correlates with decreased tumor burden in an in vivo xenograft model (M. Pusey and L. Rice, manuscript in preparation). Similarly, depletion of PME-1 decreases cancerous phenotypes in HeLa cervical cancer cell lines [26] , suggesting that chemical inhibition of PME-1 would be beneficial in cancer treatment.
There have been successful high-throughput screening campaigns to identify novel and specific inhibitors of PME-1. Bachovchin and colleagues identified two classes of covalent inhibitors of PME-1 -aza-β-lactams and sulfonyl acrylonitriles [38] [39] . Both classes were demonstrated to be specific for PME-1 over other serine hydrolases. To date, no studies have been published that demonstrate in vivo efficacy on tumor models using these compounds. We have not been able to optimize conditions for intratumoral delivery using ABL-127 [39] due to solubility issues with the compound.
Lee and colleagues demonstrated that a natural component of coffee, eicosanoyl-5-hydroxytryptamide (EHT), effectively inhibits PME-1 and demonstrated the in vivo efficacy of EHT in models for Parkinson's disease (PD), where PP2A activity is important in preventing aggregation of α-synuclein [40] [41] . Recently, Basurto-Islas and colleagues described EHT to be protective for Alzheimer's Disease (AD) in a rat model [42] . PP2A prevents neurodegeneration and onset of dementia via dephosphorylation of Tau and amyloid β proteins. These studies suggest that chemical inhibition of PME-1 is possible in vivo. The current PME-1 inhibitors suffer from poor solubility and have been difficult to validate in vitro/in vivo; however, studies exploring these small molecules are necessary to fully vet PME-1 as a therapeutic target for cancer. Thus, the discovery of novel PME-1 inhibitors with more drug-like characteristics is necessary.
PME-1 as a Biomarker
Analysis of samples harvested from patients diagnosed with endometrial adenocarcinoma demonstrated that the levels of PME-1 mRNA and protein were significantly increased in tumors versus normal adjacent tissue [27] . We further demonstrated that cells expressing PME-1 in FIGO grade 3 tumors co-expressed P-cadherin, a marker of EC aggressivity [43] , and lost E-cadherin expression, a marker of epithelial cells.
Puustinen and colleagues demonstrated that PME-1 positivity in glioblastoma patient samples correlated with increased ERK signaling and proliferation [26] . Taken together, these data suggest that PME-1 is over-expressed in human tumors compared to normal tissues and may therefore serve as a biomarker for cancer diagnosis. Additionally, PME-1 expression may also correlate with increased cancerous phenotypes and thus serve as a prognostic indicator and/or marker of treatment efficacy. In order to fully investigate PME-1 as a biomarker, studies using larger sample sizes are necessary. It will also be of interest to determine if PME-1 can be detected in biofluids to allow for less invasive diagnostic techniques. Figure 2 . Model for binding of PME-1 to the catalytic subunit of PP2A. For simplicity, the catalytic subunit of PP2A, Ppp2ca or Ppp2cb, is shown alone; however, in cells, Ppp2ca/b would be bound to the A scaffolding subunit, PR65/A. (a) When PME-1 is not bound to Ppp2ca/b, its active site is in the "closed" conformation. (b) Upon association of PME-1 with the active site of Ppp2ca/b, indicated by the arrow, PME-1 is activated, denoted by the opening of the PME-1 active site. (c) Once activated, the "open" active site of PME-1 receives the Cterminal tail of Ppp2ca/b to demethylate L309.
Conclusion
To date, there has been little success in targeting single cell signaling pathways, such as the Ras/Raf pathway, due to chemoresistance; however, there has been momentum in targeting two or more signaling pathways simultaneously [44] . Though inhibiting PME-1 may come with challenges, such as the complex biology of the system (Figure 2 , [36] ), there is emerging evidence that PME-1 inactivation is beneficial in cancer [25] [26] [27] . PP2A activation due to PME-1 inhibition in cancer would lead to simultaneous downregulation of Akt, ERK, [25] [26] [27] and Wnt pathways ( Figure 1 , [2] ), while stabilizing tumor suppressors such as p53, p21, [6] and pRb family members [45] . Thus, the inhibition of PME-1 alone could effectively inhibit multiple cell signaling pathways decreasing the chance for chemoresistance. Even though early in vivo work has investigated the inhibition of PME-1 in neuropathies [37] [38] [39] , these studies support PME-1 as a druggable and therapeutic target for malignancies.
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